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Background: Glutamine metabolism is a central metabolic pathway in cancer. Recently, reductive carboxylation
of glutamine for lipogenesis has been shown to constitute a key anabolic route in cancer cells. However, little is
known regarding central regulators of the various glutamine metabolic pathways in cancer cells.
Methods: The impact of PGC-1α and ERRα on glutamine enzyme expression was assessed in ERBB2+ breast cancer
cell lines with quantitative RT-PCR, chromatin immunoprecipitation, and immunoblotting experiments. Glutamine
flux was quantified using 13C-labeled glutamine and GC/MS analyses. Functional assays for lipogenesis were
performed using 14C-labeled glutamine. The expression of glutamine metabolism genes in breast cancer patients
was determined by bioinformatics analyses using The Cancer Genome Atlas.
Results: We show that the transcriptional coactivator PGC-1α, along with the transcription factor ERRα, is a positive
regulator of the expression of glutamine metabolism genes in ERBB2+ breast cancer. Indeed, ERBB2+ breast cancer
cells with increased expression of PGC-1α display elevated expression of glutamine metabolism genes. Furthermore,
ERBB2+ breast cancer cells with reduced expression of PGC-1α or when treated with C29, a pharmacological
inhibitor of ERRα, exhibit diminished expression of glutamine metabolism genes. The biological relevance of the
control of glutamine metabolism genes by the PGC-1α/ERRα axis is demonstrated by consequent regulation of
glutamine flux through the citric acid cycle. PGC-1α and ERRα regulate both the canonical citric acid cycle (forward)
and the reductive carboxylation (reverse) fluxes; the latter can be used to support de novo lipogenesis reactions,
most notably in hypoxic conditions. Importantly, murine and human ERBB2+ cells lines display a significant
dependence on glutamine availability for their growth. Finally, we show that PGC-1α expression is positively
correlated with that of the glutamine pathway in ERBB2+ breast cancer patients, and high expression of this
pathway is associated with reduced patient survival.
Conclusions: These data reveal that the PGC-1α/ERRα axis is a central regulator of glutamine metabolism in
ERBB2+ breast cancer. This novel regulatory link, as well as the marked reduction in patient survival time associated
with increased glutamine pathway gene expression, suggests that targeting glutamine metabolism may have
therapeutic potential in the treatment of ERBB2+ breast cancer.
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Altered metabolism is an emerging hallmark of cancer
cells [1]. The most studied metabolic alteration of cancer
cells is their high reliance on glycolysis even if there is
sufficient oxygen to support mitochondrial oxidative
phosphorylation (Warburg effect). The rapid ATP pro-
duction of glycolysis is thought to benefit the enhanced
proliferation of cancer cells. However, glutamine metab-
olism has been increasingly recognized as a central
metabolic pathway in cancer, and it is thought that the
catabolic and anabolic roles of glucose and glutamine
cooperate in fuelling tumor growth [2]. The discovery
that the oncogene Myc is an important regulator of glu-
tamine metabolism has further strengthened the import-
ance of this metabolic pathway in cancer [3,4].
Recent studies revealed that reductive carboxylation of
glutamine to citrate through reversal of the citric acid
cycle (CAC) and the subsequent use of citrate for lipo-
genesis constitute a key anabolic route in hypoxia in
cancer cells, as well as in cancer cells with mitochondrial
dysfunctions [5-8]. Hypoxia-induced factor 1 (HIF-1)
plays an important role in this metabolic reprogram-
ming, as cells constitutively expressing HIF-1α perform
reductive carboxylation of glutamine in normoxia [5,7].
Clearly, the ability to rely on this metabolic pathway will
be a distinct advantage for solid tumors that experience
fluctuating levels of oxygen by permitting elevated pro-
duction of lipids, which are important notably for mem-
brane biogenesis.
The family of peroxisome proliferator activated recep-
tor gamma coactivator 1 (PGC-1) consists of three
members, PGC-1α, PGC-1β, and PRC. These transcrip-
tional coactivators play a central role in metabolism
[9,10]. Even though the importance of the PGC-1s in
regulating mitochondrial functions and metabolism is
well established in general, their roles in regulating
cancer metabolism and proliferation have only started to
emerge recently. The PGC-1s have been shown to have
both pro- and anti-tumorigenesis effects [11,12]. In
breast cancer, PGC-1α has been shown to promote the
growth of ERBB2+ tumors in vivo and to regulate their
mitochondrial metabolism and angiogenic properties
[12,13]. In this paper, we inquired whether PGC-1α par-
ticipates in the control of glutamine metabolism in
breast cancer. We reveal that PGC-1α increases the ex-
pression of glutamine metabolism genes, augments
glutamine-mediated forward and reverse CAC fluxes, as
well as elevates glutamine-mediated lipogenesis in hyp-
oxia. This PGC-1α-mediated increase in glutamine me-
tabolism will confer an advantage to solid breast cancer
tumors experiencing limited nutrients and oxygen sup-
ply. Relevance to the human disease is underlined by the
findings that PGC-1α expression is positively correlated
with that of the glutamine pathway in ERBB2+ breastcancer patients, and that high expression of the glutam-
ine pathway is associated with shorter survival time.
Methods
Animals
All procedures were conducted in accordance with ap-
proved animal protocols by the McGill University Ani-
mal Care Committee. Wild-type mice (C57BL/6J) and
muscle creatine kinase (mck)-PGC-1α transgenic mice
(C57BL/6-Tg(Ckm-Ppargc1a)31Brsp/J) as described in
[14] were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). All animals used were female and
were sacrificed at approximately 12 weeks of age.
Tissue culture
Stable cell lines Control-1, PGC-1α-1.1, and PGC-1α-1.2
have been described in [13]. These cells were cultured in
Dulbecco's Modified Eagle's Medium (DMEM), 10%
FBS, 10 μg/mL insulin, 20 mM HEPES, penicillin/
streptomycin, 1 μg/mL puromycin, 400 μg/mL G418, at
37°C and 5% CO2. SK-BR-3 and BT-474 were obtained
from the American Type Culture Collection (ATCC)
and cultured in DMEM supplemented with 10% FBS
and penicillin/streptomycin. Hypoxia experiments were
performed in a Thermo Scientific (Rockford, IL, USA)
Heraeus HERAcell 150 set at 1% O2 and 5% CO2.
Pharmacological inhibition of ERRα was performed
using Compound 29 (C29) at 5 μM (0.1% DMSO). C29
was synthesized according to [15].
Gene expression
Total RNA from cultured cells, grown to 50% to 60%
confluence in 35 mm plates, was extracted using the
Aurum Total RNA Mini Kit (Bio-Rad, Mississauga,
Canada) and was reverse transcribed with iScript cDNA
Synthesis kit (Bio-Rad). mRNA expression analyses by
real-time PCR were performed using iQ SYBR Green
Supermix (Bio-Rad) and gene-specific primers with the
MyiQ2 Real-Time Detection System (Bio-Rad). Values
were normalized to TATA binding protein (Tbp) for
murine cell lines or beta-2 microglobulin (B2M) for hu-
man cell lines.
Chromatin immunoprecipitation
Chromatin was prepared from PGC-1α-1.1 cells, using
approximately 107 cells per chromatin immunoprecipita-
tion (ChIP). ChIP was performed as described previously
[16] using a specific anti-PGC-1α antibody (Santa Cruz
Biotechnology, Inc., Dallas, TX, USA, catalog #sc-13067)
or specific anti-ERRα antibody (Epitomics, Burlingame,
CA, USA, catalog #2131-1). Quantification of PGC-1α
or ERRα ChIP enrichment was performed using real-
time PCR using the LightCycler 480 instrument (Roche,
Mississauga, Canada) and specific primers for genomic
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control region and further normalized against the IgG
control.
Immunoblotting
Total proteins from cultured cells or muscle tissue were
extracted with lysis buffer (50 mM Tris–HCl pH 7.4, 1%
Triton X-100, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA) with inhibitors (2 μg/mL pepstatin,
1 μg/mL aprotinin, 1 μg/mL leupeptin, 0.2 mM phenyl-
methylsulfonyl fluoride and 1 mM sodium orthovana-
date) and quantified with the Bio-Rad Protein Assay kit
(Catalog #500-0006). The blots were incubated accord-
ing to the manufacturer's instructions with the following
primary antibodies: Glud1 (GeneTex, Irvine, CA, USA,
GTX88164), Gls (Abcam, Toronto, Canada, AB93434),
Got1 (GeneTex, GTX88903), Got2 (GeneTex,
GTX88925), Hsp90 (Santa Cruz Biotechnology, sc-
101494), and Actin (Santa Cruz Biotechnology, sc-1616)
and with horseradish peroxidase-conjugated secondary
antibodies (GE Healthcare, Mississauga, Canada, or
Santa Cruz Biotechnology). The results were visualized
using Western Lightning Plus-ECL (Perkin Elmer,
Waltham, MA, USA) or SuperSignal West Femto ECL
(Pierce, Rockford, IL, USA). Densitometry analyses were
conducted using ImageJ software (NIH).
siRNA
BT-474 cells were subjected to either 10 nM control
siRNA (Dharmacon, Rockford, IL, USA, D-001810-10-
05) or a combined 10 nM pool of four siRNA specifically
targeting PPARGC1A (Qiagen, Germantown, MD, USA,
FlexiTube GeneSolution GS10891). Cells were trans-
fected using calcium phosphate (CaPO4) and incubated
for 120 h before extraction.
14C-lipid incorporation assay
Cells were seeded at a density of 400,000 cells per
35 mm plate in standard growth media and conditions.
After 24 h, the medium was supplemented with trace
amounts of [U-14C]-glutamine (0.094 μCi/mL) and the
cells were further incubated either in normoxia (21%
O2) or hypoxia (1% O2) for 24 h (Control-1 and PGC-
1α-1.1) or 48 h (BT-474). Individual experiments were
conducted in triplicate with additional plates for cell
counting. Cells were washed with PBS, collected using
0.5% Triton X-100, and stored at −80°C. After thawing,
lipids were extracted using chloroform/methanol; the
lipid-rich chloroform phase was dried under air and re-
suspended in 150 μL chloroform. Scintillation counts
were measured over 5 minutes per sample using a
MicroBeta2 scintillation counter (Perkin-Elmer) and
Eco-Lume reagent (MPBio, Solon, OH, USA). Counts
were normalized for cell number.Glutamine uptake
Cellular glutamine uptake was measured using the Bio-
Profile 400 analyzer (Nova Biomedical Corp., Waltham,
MA, USA). Following growth under normoxic (21% O2)
or hypoxic (1% O2) conditions, media were removed and
maintained on ice until analysis. Glutamine uptake was
calculated as the difference in glutamine content be-
tween culture media and unseeded media incubated in
parallel plates and normalized for cell count.
Mass isotopomer distribution analysis
The metabolomics analyses by GC/MS were adapted from
[17]. Additional details are provided in Additional file 1.
The Cancer Genome Atlas analyses
Breast cancer data, clinical data, and survival data for
732 patients were obtained from The Cancer Genome
Atlas (TCGA) [18]. RNAseq data were downloaded from
TCGA web portal using the reads per kilobase of exon
model per million mapped reads (RPKM) quantification
[19]. RPKM data was log2 transformed and expression
values lower than 0.25 RPKM were removed. To gener-
ate an overall pathway score, all nine genes in the glu-
tamine metabolism pathway were Z-transformed (mean
0 and standard deviation of 1). Mean of zero corrects for
the fact that the genes may be expressed at different
levels. Transforming the standard deviation to 1 causes
the genes to change in the same magnitude, so we can
see if the overall pathway is over/underexpressed. If the
genes are expressed at different levels, the changes in
the pathway will be dominated by the genes that were
originally expressed at higher levels. We used the me-
dian of Z-scores to generate a pathway score, which was
used in correlation and survival analysis.
Statistical analyses
All statistical analyses were performed using GraphPad
Prism (GraphPad Software, Inc., CA, USA), Microsoft
Excel (Microsoft Corporation, CA, USA) or Matlab (The
Mathworks, Inc., MA, USA). Survival analysis was calcu-
lated using an implementation of Kaplan-Meir log rank
testing from Matlab Exchange [20].
Additional methods
Additional methods are provided in Additional file 1 and
in Additional file 2: Table S1.
Results
PGC-1α modulates the expression of enzymes involved in
glutamine metabolism in ERBB2/Neu-induced breast
cancer cells
To assess the impact of PGC-1α on the expression of
glutamine metabolism genes, we used clones of ERBB2/
Neu-induced breast cancer cells with modestly increased
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(Ctl-1) [13]. These cells have been extensively character-
ized [13], and as expected, they display an approximately
30% increase in expression of well-known PGC-1α mito-
chondrial target genes [13] [see Additional file 3: Figure
S1A]. Here we reveal that the mRNA expression of en-
zymes involved in glutamine catabolism, transport, and
synthesis were significantly increased in PGC-1α clones
compared with control (Figure 1A,B). In support of this
point, cells with reduced expression of PGC-1α dis-
played lowered expression of glutamine metabolism
genes [see Additional file 3: Figure S1B]. In addition,
PGC-1α controls these genes in a cancer-independent
context, as PGC-1α muscle-specific transgenic animalsFigure 1 PGC-1α modulates the expression of glutamine metabolism
cells. SLC1A5, solute carrier family 1, member 5; GLS1, kidney-type glutaminas
GOT2, mitochondrial glutamic-oxaloacetic transaminase; GPT2, mitochondrial
transaminase; GPT1, cytoplasmic glutamic pyruvate transaminase; GLUL, gluta
Asp, aspartate; Pyr, pyruvate; Ala, alanine; α-KG, α-ketoglutarate; CAC, citric acid
Neu-induced breast cancer cells (NT2196) with increased expression of PGC-1
as means ± S.E.M., n = 4. *P <0.05, paired Student's t-test. (C) ChIP analyses for PG
genes in NT2196 cells with increased expression of PGC-1α (α-1.1). Data represen
western blot for select glutamine metabolism enzymes in NT2196 cells with incre
of five independent western blot experiments, normalized to ACTIN levels. Data aexhibited increased expression of several glutamine me-
tabolism genes [see Additional file 3: Figure S1C,D].
Given the known functional relationship between PGC-
1α and the estrogen-related receptor α (ERRα) in the
control of metabolism genes [10], we tested whether
PGC-1α could be recruited at promoter sites targeted by
ERRα using chromatin immunoprecipitation (ChIP) ex-
periments. ERBB2/Neu-induced breast cancer cells with
increased expression of PGC-1α (α-1.1) displayed two-
fold enrichment or greater for PGC-1α and ERRα at the
promoter of glutamine metabolism genes (Figure 1C),
supporting the tight association between the ERRs and
PGC-1 s in the control of metabolic genes [10,12]. Fi-
nally, we confirmed that the PGC-1α-mediated increaseenzymes. (A) Schematic representation of glutamine metabolism in
e; GLS2, liver-type glutaminase; GLUD1, glutamate dehydrogenase 1;
glutamic pyruvate transaminase; GOT1, cytoplasmic glutamic-oxaloacetic
mate-ammonia ligase; Gln, glutamine; Glu, glutamate; OAA, oxaloacetate;
cycle. (B) Expression of glutamine metabolism genes in ERBB2/
α (α-1.1, α-1.2) normalized to that in control cells. Data are presented
C-1α and ERRα at ERRE sites on the promoter of glutamine metabolism
t the fold enrichment for two independent experiments. (D) Representative
ased expression of PGC-1α (α-1.1, α-1.2) and control (Ctl-1). (E) Quantification
re presented as means ± S.E.M., n = 5. *P <0.05, paired Student's t-test.
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approximately two-fold or greater increase in protein
levels (Figure 1D,E). This coordinated augmentation in
mRNA and protein expression, in addition to corre-
sponding enrichments observed in ChIP analyses, dem-
onstrates that PGC-1α and ERRα exert a concerted control
of glutamine metabolism genes; such pathway control has
been shown to have strong biological relevance [21].
PGC-1α/ERRα modulate forward and reverse glutamine
flux through the citric acid cycle
To demonstrate the biological significance of the changes
in glutamine gene expression, we first quantified relative
glutamine uptake in ERBB2/Neu-induced breast cancer
cells with increased expression of PGC-1α (α-1.1) and con-
trol cells. The α-1.1 cells showed a 25% increase in glutam-
ine uptake both in normoxia and hypoxia compared with
control (Figure 2A). This increase is similar in magnitude
to that elicited by oncogenic levels of Myc [3].Figure 2 PGC-1α modulates glutamine metabolism in normoxia and h
expression of PGC-1α (α-1.1) and control. Cells were cultured in either norm
α-1.1 cells compared to control. Data are presented as means ± S.E.M., n = 5
depicting metabolomics experiments using [U-13C]-glutamine to evaluate f
13C is represented as black circles and endogenous 12C as white circles. (C)
increased expression of PGC-1α (α-1.1) and control (Ctl-1) pulsed with [U-13
means ± S.E.M., n = 6. †P <0.05, paired Student's t-test. (D) Mass isotopome
*(m + 4, forward flux) and †(m + 5, reverse flux) P <0.05, paired Student's t-t
means ± S.E.M., n = 6. *(m + 4, forward flux) and †(m + 3, reverse flux) P <0.0
Data are presented as means ± S.E.M., n = 6. *(m + 4, forward flux) and †(m
normalized ion amounts were calculated as normalized MDV* multiplied bTo gain insight on the flux of glutamine upon in-
creased PGC-1α expression, α-1.1 and control cells were
incubated with [U-13C]-glutamine labelled at all five car-
bons (Figure 2B). α-ketoglutarate m + 5 is generated
from glutamine m + 5 ([U-13C]-glutamine) and serves as
an entry point in the CAC, where it can either generate
isocitrate m + 5 by reductive carboxylation (reverse flux)
or succinate m + 4 by oxidative decarboxylation (forward
flux) (Figure 2B). Reverse CAC flux leads to enrichments
in citrate m + 5, malate m + 3, and fumarate m + 3, and
forward CAC leads to the enrichment of m + 4 metabolites
(Figure 2B). Citrate m + 4 and m+ 5 can be used for lipid
biosynthesis, but citrate generated specifically through re-
verse CAC (m+ 5) plays a central role in glutamine-
derived lipogenesis in cancer cells (Figure 2B) [5-7].
We performed glutamine labeling experiments in nor-
moxia and hypoxia given that reductive carboxylation of
glutamine is particularly active in hypoxia [5-7]. In
normoxia, α-1.1 cells displayed increased entry ofypoxia. (A) Glutamine uptake in NT2196 cells with increased
oxia or hypoxia for 24 h. Data are represented as fold difference for
. *P <0.05, paired Student's t-test. (B) Schematic representation
orward (green) and reverse (red) citric acid cycle (CAC) fluxes. Herein,
Mass isotopomer enrichment of α-ketoglutarate in NT2196 cells with
C]-glutamine in normoxia and hypoxia. Data are presented as
r enrichment of citrate. Data are presented as means ± S.E.M., n = 6.
est. (E) Mass isotopomer enrichment of malate. Data are presented as
5, paired Student's t-test. (F) Mass isotopomer enrichment of fumarate.
+ 3, reverse flux) P <0.05, paired Student's t-test. For panels C-F,
y fold change in steady state levels, relative to Ctl-1 cells in normoxia.
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of m + 5 α-ketoglutarate compared with control
(Figure 2C). The α-ketoglutarate can then enter both the
forward and reverse CAC reactions. The α-1.1 cells dis-
played higher forward and reverse CAC activity com-
pared with controls (Figure 2C-F). The elevated forward
flux can be seen from the higher amount of m + 4 cit-
rate, malate, and fumarate, while the elevated reverse
flux can be observed in the higher amount of m + 5 cit-
rate as well as m + 3 malate and fumarate (Figure 2D-F)
[see Additional file 4: Figure S2A]. The reverse flux rep-
resented a small fraction of the total CAC flux in nor-
moxia. In hypoxia, there was an increase in the entry of
glutamine in the CAC at α-ketoglutarate both for the
control and α-1.1 cells compared with normoxia
(Figure 2C). In general, hypoxia caused an increase in
the reverse flux for both the control and α-1.1 cells
(Figure 2D-F) [see Additional file 4: Figure S2A], but theFigure 3 ERRα modulates glutamine metabolism in normoxia and hyp
treated with ERRα inhibitor C29 and cultured in either normoxia or hypoxia
represented as means ± S.E.M., from three biological replicates representati
(B) Expression of glutamine metabolism genes in BT-474 cells treated with
normalized to normoxic control cells. Data are represented as means ± S.E.M
(C) Mass isotopomer distribution analysis of CAC intermediates in SK-BR-3 a
[U-13C]-glutamine. For SK-BR-3, data are represented as means ± S.E.M., from
experiments. *P <0.05, unpaired Student's t-test. For BT-474, data are repres
paired Student's t-test. For panel C, relative ion levels represent specific maeffects were more pronounced in the α-1.1 cells and can
be best appreciated when examining the labeling on cit-
rate (Figure 2D). Indeed, α-1.1 cells displayed a large
m + 5 labeling on citrate in hypoxia and devoted a larger
fraction of their CAC flux for reverse reactions than
control cells in hypoxia (Figure 2D). Together, these
metabolomics experiments illustrate that PGC-1α can
stimulate glutamine-mediated forward and reverse CAC
fluxes in normoxia and hypoxia.
Next, we investigated whether ERRα could also regu-
late glutamine flux through the CAC given that it can be
recruited with PGC-1α to the promoter of glutamine
metabolism genes. To do so, we used the ERRα pharma-
cological inhibitor C29 [15] in the ERBB2+ human
breast cancer cell lines SK-BR-3 and BT-474. Treatment
of SK-BR-3 cells with C29 both in normoxia and hypoxia
decreased the expression of glutamine metabolism and
CAC genes (Figure 3A). This is supported by aoxia. (A) Expression of glutamine metabolism genes in SK-BR-3 cells
for 24 h. Expression is normalized to normoxic control cells. Data are
ve of two independent experiments. *P <0.05, unpaired Student's t-test.
C29 and cultured in either normoxia or hypoxia for 24 h. Expression is
., from four independent cultures. *P <0.05, paired Student's t-test.
nd BT-474 cells treated as in A and B, respectively, and pulsed with
three biological replicates representative of two independent
ented as means ± S.E.M., from four independent cultures. *P <0.05,
ss isotopomer fractions normalized to that of control cells in normoxia.
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levels [see Additional file 5: Figure S3]. In agreement
with these changes, SK-BR-3 cells treated with C29 dis-
played a decrease in forward CAC flux, most notably in
hypoxia, illustrated by reduced fraction of m + 4 citrate,
malate, and fumarate (Figure 3C). The reverse CAC flux
was significantly decreased in the presence of C29 in
normoxia and hypoxia, demonstrated by a reduced frac-
tion of m + 5 α-ketoglutarate and citrate as well as m + 3
malate and fumarate (Figure 3C). In BT-474 cells, C29
decreased the expression of glutamine metabolism and
CAC genes and also reduced forward and reverse CAC
fluxes in hypoxia (Figure 3B,C). The lack of effect of C29
in BT-474 cells in normoxia is most likely explained by
the fact that these cells are not as dependent on ERRα
activity as SK-BR-3 cells under standard conditions [22].
Together, the metabolite flux experiments performed
with PGC-1α and ERRα illustrate that they both play a
central role in controlling glutamine-mediated forward
and reverse CAC fluxes in ERBB2+ breast cancer cells.
It is important to note that we did not detect glutamine-
derived lactate in all ERBB2+ cells we tested [see Add-
itional file 4: Figure S2B-D].PGC-1α increases glutamine-mediated fatty acid
biosynthesis and favors proliferation in limited nutrient
conditions
One central function of glutamine metabolism is to replen-
ish the CAC of intermediates that are used for biosynthetic
processes, notably citrate that is used in lipid synthesis [2].
Indeed, glutamine has been shown to play a central role in
lipid biosynthesis in cancer cells [23,24]. We measured the
impact of PGC-1α on the expression of key genes involved
in lipid biosynthesis. ERBB2/Neu-induced breast cancer
cells with increased expression of PGC-1α (α-1.1 and α-1.2)
displayed an elevated expression of lipogenic genes com-
pared with control cells (Ctl-1; Figure 4A,B). In order to de-
termine the involvement of PGC-1α in glutamine-mediated
lipid biosynthesis, we incubated α-1.1 cells and control with
trace amounts of [U-14C]-glutamine and monitored 14C in-
corporation in whole lipid extracts. The α-1.1 cells dis-
played a significant (48%) increase in 14C incorporation
compared with controls in normoxia, as well as a robust
(63%) increase in 14C incorporation compared with controls
in hypoxia (Figure 4C). As expected, there was an import-
ant increase in glutamine-mediated lipid biosynthesis in
hypoxia in both control and α-1.1 cells (Figure 4C) [7].
Also, ERRα is an important regulator of glutamine-
mediated lipogenesis as BT-474 cells treated with C29 elic-
ited a significant (62%) decrease in [U-14C]-glutamine in-
corporation into lipids in hypoxia [see Additional file 6:
Figure S4A]. These data illustrate that PGC-1α and ERRα
are key regulators of glutamine-mediated lipid biosynthesis.Next, we tested the impact of PGC-1α on the sensitiv-
ity of ERBB2/Neu-induced breast cancer cells to glutam-
ine deprivation, low glucose, and hypoxia, in order to
mimic the environment of solid growing tumors. The
growth of both ERBB2/Neu-induced breast cancer cells
with increased expression of PGC-1α (α-1.1) and con-
trols was ablated in the absence of glutamine (Figure 4D),
illustrating that ERBB2/Neu-induced breast cancer cells
require glutamine for their growth. A similar depend-
ency on glutamine was observed with human ERBB2+
breast cancer cell lines [see Additional file 6: Figure S4B,
C]. We then tested the impact of PGC-1α on cellular
proliferation in low glucose and hypoxia, two conditions
that can favor glutamine usage (Figure 4E) [5,7,25]. The
proliferation of α-1.1 cells was less sensitive to a com-
bination of low glucose and hypoxia than controls as in-
dicated by their smaller reduction in proliferation
(Figure 4E). Together, these data demonstrate that glutam-
ine is a key metabolite for the growth of ERBB2/Neu-in-
duced breast cancer cells, and that the PGC-1α-mediated
increase in glutamine metabolism is associated with pro-
tection against low glucose conditions and hypoxia, two
conditions that can favor glutamine metabolism.Gene expression analyses of PGC-1α and glutamine
enzymes in breast cancer patients
We examined the expression of PGC-1α (PPARGC1A)
and glutamine enzymes in 732 breast cancer patients
from The Cancer Genome Atlas (TCGA) to determine
their expression pattern across breast cancer subtypes
and correlation with survival. PPARGC1A expression
was highest in basal and ERBB2-enriched breast cancer
subtypes, which have poorer prognosis than luminal A
and B subtypes (Figure 5A). The expression of glutamine
enzymes (glutamine cluster) was positively correlated
with PPARGC1A expression in the basal and ERBB2-
enriched breast cancer subtypes, in agreement with the
fact that these subtypes have the highest expression of
PPARGC1A (Figure 5B). Then, we determined if the ex-
pression of the glutamine cluster was correlated with
clinical outcome. High expression of the glutamine clus-
ter was associated with reduced survival in ERBB2-
enriched and luminal B subtypes, and this association
held true when looking at all breast cancer patients
(Figure 5B,C). The fact that high expression of the glu-
tamine cluster is associated with reduced survival in lu-
minal B subtype but is not positively correlated with
PPARGC1A expression suggests that, while glutamine
metabolism is clinically relevant in this subtype, factors
other than PGC-1α are driving the expression of this
pathway. Overall, these data provide clinical relevance to
the notion that PGC-1α is a central regulator of glutam-
ine metabolism in ERBB2+ breast cancer cells.
Figure 4 PGC-1α promotes glutamine-mediated lipid biosynthesis and favors proliferation in limited nutrient conditions. (A) Schematic
representation depicting lipogenesis from glutamine through reverse citric acid cycle (CAC) activity. Glutamine-derived α-ketoglutarate is
converted to isocitrate by mitochondrial NADP+/NADPH-dependent isocitrate dehydrogenase (IDH2), producing citrate. Citrate is exported to
the cytoplasm to generate acetyl CoA and oxaloacetate via ATP citrate lyase (ACLY). Acetyl CoA is converted to malonyl CoA by acetyl CoA
carboxylase (ACC). Iterative additions of acetyl CoA to malonyl CoA by fatty acid synthase (FAS) yield fatty acid products (shown: palmitate). Gln,
glutamine; Glu, glutamate; OAA, oxaloacetate; GLS1, kidney-type glutaminase; GLS2, liver-type glutaminase; GLUD1, glutamate dehydrogenase 1;
GOT2, mitochondrial glutamic-oxaloacetic transaminase; GPT2, mitochondrial glutamic pyruvate transaminase. (B) Expression of lipogenic genes in
ERBB2/Neu-induced breast cancer cells (NT2196) with increased expression of PGC-1α (α-1.1, α-1.2) normalized to that in control cells. Data are
presented as means ± S.E.M., n = 3. *P <0.05, paired Student's t-test. (C) Incorporation of 14C into lipids from trace [U-14C]-glutamine in α-1.1 and
Ctl-1 cells under normoxia or hypoxia. Counts were normalized for cell number and expressed relative to that of control cells in normoxia. Data
are presented as means ± S.E.M., n = 6. *P <0.05, paired Student's t-test. (D) Relative proliferation of α-1.1 and Ctl-1 cells in the absence of
glutamine compared to proliferation in standard glutamine conditions. Data are presented as fold values of cell count in standard glutamine
conditions at 5 days ± S.E.M., n = 6. *P <0.05, paired Student's t-test. (E) Relative proliferation of α-1.1 and Ctl-1 cells in hypoxia under low glucose
conditions compared to proliferation in normoxia and standard glucose conditions. Data are presented as fold values of cell count in normoxia
and standard glucose conditions at 6 days ± S.E.M., n = 4. *P <0.05, paired Student's t-test.
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In this manuscript, we report that the PGC-1α/ERRα
axis is a key regulator of glutamine metabolism in
ERBB2+ breast cancer cells. We revealed that PGC-1α/
ERRα bind the promoter of glutamine metabolism genes
and regulate their expression, which ultimately controls
the flux of glutamine in cells. This can contribute to
increased lipid biosynthesis, especially under hypoxicconditions. Finally, we demonstrate that the PGC-1α-
mediated control of glutamine metabolism has clinical
relevance in ERBB2+ breast cancer patients.
Even though the importance of glutamine metabolism
in cancer cells is well appreciated, much less is known
regarding central regulators of glutamine metabolic
pathways. Major transcriptional regulators of glutamine
metabolism identified so far are c-Myc [3,4,26,27] and
Figure 5 Expression analyses of PGC-1α and glutamine pathway in breast cancer patients. (A) Expression of PGC-1α across the different
breast cancer clinical subtypes in The Cancer Genome Atlas (TCGA) data set, where crosses represent outliers for this subtype. Expression is given
in log2-normalized reads per kilobase of exon model per million mapped reads (RPKM). The number of samples for Basal-like, ERBB2-enriched,
Luminal A, Luminal B, and Normal-like is 87, 53, 201, 110, and 7, respectively. PGC-1α expression is higher in basal than luminal A and B subtypes,
higher in luminal A subtype than luminal B subtype, and higher in ERBB2-enriched than luminal B subtype. P <1E-13 for Kruskal-Wallis, *P <0.05
using a posteriori Tukey-Kramer test. (B) (top) Expression of the glutamine metabolism genes is correlated with that of PGC-1α. The table shows
the Pearson correlation coefficients between PGC-1α expression and the pathway score of the glutamine cluster. Colors represent the intensity of
correlation as per the gradient shown. (bottom) Patient survival is related to glutamine cluster expression. The table shows P values for survival.
Higher expression of glutamine cluster correlated with reduced survival in ERBB2-enriched and luminal B subtypes as well as in combined
subtypes. Green arrows represent significant differences. P <0.05, logrank test. (C) High expression of glutamine metabolism genes is associated
with reduced survival in all patients (all subtypes, left) and ERBB2-enriched patients (right). Kaplan-Meier survival curves represent the differences
in survival between patients with high and low expression of the glutamine cluster.
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are central regulators of glutamine-mediated forward
and reverse CAC fluxes. Interestingly, a recent report
showed that glutamine reductive carboxylation for lipo-
genesis is particularly active in brown fat cells [28], the
same cell type where PGC-1α was discovered and which
display very high expression of this coactivator [29]. In
recent years, PGC-1s/ERRs have been involved in the
control of the expression of numerous metabolic
pathways in breast cancer cells [12,22,30]. Both PGC-1α
and ERRα have been shown to promote the growth of
ERBB2+ tumors in vivo and to regulate the metabolismof this specific breast cancer subtype [12,13,22,31]. Inter-
estingly, increased expression of PGC-1α reduced the
proliferation of ERBB2+ cells in vitro, but promoted
tumor growth in vivo by promoting nutrient supply [13].
We show here that ERBB2+ cells are dependent on glu-
tamine for their growth as complete glutamine removal
from cell culture severely compromised cell growth. Al-
though the glucose dependence of ERBB2+ cells is well
known [32], the role of glutamine in this system has been
largely overlooked. A point supporting the importance of
glutamine in ERBB2+ tumors is the observation that
ERBB2 signaling elevates c-Myc expression, which is a
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more, it would not be surprising that the pro-growth effect
of PGC-1α and ERRα in ERBB2+ tumors is mediated at
least in part through their positive impact on glutamine
metabolism. In support of this point, the expression of
PGC-1α and that of the glutamine pathway are positively
correlated in ERBB2+ breast cancer patients, and high ex-
pression of glutamine metabolism enzymes is associated
with shorter survival. It is important to emphasize that we
do not exclude the possibility that PGC-1α may associate
with other transcription factors, in addition to ERRα, to
control the expression of glutamine metabolism genes.
Conclusions
In this paper, we reveal that the PGC-1α/ERRα axis is a
central regulator of glutamine metabolism in ERBB2+
breast cancer. PGC-1α/ERRα likely regulate similar
metabolic programs in diverse cancer types as the meta-
bolic targets of PGC-1α/ERRα in various normal tissues
and cancer cells/tumors are similar. The positive or
negative impact of PGC-1α/ERRα on tumor growth will
depend on the specific metabolic alterations of each
tumor. There is significant effort currently underway to
associate metabolic signatures to specific oncogenes.
Furthermore, it is important to appreciate that the PGC-
1α/ERRα axis also regulates the expression of genes not
directly associated with metabolism; these genes may be
equally or even more important in defining the roles of
PGC-1α/ERRα in various cancer types. For example,
ERRα regulates the expression of genes located in the
ERBB2 amplicon that are involved in signal transduction,
cell migration and invasion, as well as tamoxifen resist-
ance [31]. Overall, much remains to be discovered
regarding the importance of PGC-1α/ERRα in con-
tributing to the altered metabolism of various cancer
types and to link this new metabolic state with clinical
outcome. Also, the importance of PGC-1α/ERRα target
genes involved in other hallmarks of cancer cells such as
migration/invasion, apoptosis, and angiogenesis [1]
needs to be established. That being said, the identifica-
tion of PGC-1α/ERRα as central regulators of glutamine
metabolism may open novel therapeutic avenues for tu-
mors showing strong dependence on this metabolic
pathway.
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mitochondrial and glutamine metabolism enzymes. (A) Expression of
mitochondrial genes in ERBB2/Neu-induced breast cancer cells (NT2196)
with increased expression of PGC-1α (α-1.1, α-1.2) normalized to that ofcontrol cells. Data are presented as means ± S.E.M., n = 6. *P <0.05, paired
Student's t-test. (B) Expression of glutamine genes in BT-474 cells treated
with siPGC-1α for 120 h normalized to that of cells treated with control
siRNA. Data are presented as means ± S.E.M., n = 4. *P <0.05, paired
Student's t-test. (C) Expression of glutamine metabolism genes in
mck-PGC-1α transgenic mice normalized to that of wild-type mice. Data
are presented as means ± S.E.M., n = 6. *P <0.05, paired Student's t-test.
(D) Representative western blot of selected glutamine metabolism
enzymes in wild-type and mck-PGC-1α transgenic mice.
Additional file 4: Figure S2. PGC-1α increases glutamine flux to malate
and fumarate, and ERBB2+ breast cancer cell lines lack glutamine-derived
pyruvate and lactate. (A) Mass isotopomer enrichment of malate and
fumarate. Data are presented as means ± S.E.M., n = 6. *P <0.05, paired
Student's t-test. (B) Mass isotopomer distribution analysis of pyruvate
(left) and lactate (right) in ERBB2/Neu-induced breast cancer cells
(NT2196) with increased expression of PGC-1α (α-1.1) and Control (Ctl-1)
under normoxia or hypoxia, and pulsed with [U-13C]-glutamine. Data are
presented as means ± S.E.M., n = 3. (C) Mass isotopomer distribution
analysis of pyruvate (left) and lactate (right) in SK-BR-3 cells under
normoxia or hypoxia. Cells were pulsed with [U-13C]-glutamine. Data
are presented as means ± S.E.M., n = 3. (D) Mass isotopomer distribution
analysis of pyruvate (left) and lactate (right) in BT-474 cells under
normoxia or hypoxia. Cells were pulsed with [U-13C]-glutamine. Data are
presented as means ± S.E.M., n = 3. For panel A, specific ion amounts are
from Figure 2E-F and were normalized to that of Ctl-1 cells in normoxia.
For panels B-D, relative ion levels represent specific mass isotopomer
fractions normalized to that of control cells in normoxia.
Additional file 5: Figure S3. ERRα modulates the expression of
glutamine metabolism enzymes (A) Representative western blot for ERRα
and select glutamine metabolism enzymes in SK-BR-3 cells treated with
ERRα inhibitor C29 and cultured in either normoxia or hypoxia for 24 h
(B) Quantification of five independent western blot experiments, normal-
ized to ACTIN levels. Data are presented as means of C29-treated SK-BR-3
cells relative to control (DMSO) ± S.E.M., n = 5. *P <0.05, paired Student's
t-test.
Additional file 6: Figure S4. ERRα promotes glutamine-mediated
lipogenesis, and glutamine deprivation limits the proliferation of human
ERBB2+ breast cancer cell lines. (A) Incorporation of 14C into lipids from
trace [U-14C]-glutamine in BT-474 cells under normoxia or hypoxia treated
with C29 or DMSO control. Counts were normalized for cell number and
expressed relative to the count of control cells in normoxia. Data are
presented as means ± S.E.M., n = 4. *P <0.05, paired Student's t-test. (B)
Proliferation of BT-474 cells in the presence or absence of glutamine.
Data are presented as means ± S.E.M., n = 3. (C) Proliferation of SK-BR-3
cells in the presence or absence of glutamine. Data are presented as
means ± S.E.M., n = 3.
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